Compare BORR & ANAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BORR | ANAB |
|---|---|---|
| Founded | 2016 | 2005 |
| Country | Bermuda | United States |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.4B | 1.6B |
| IPO Year | 2017 | 2015 |
| Metric | BORR | ANAB |
|---|---|---|
| Price | $4.15 | $49.25 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 7 | 8 |
| Target Price | $4.97 | ★ $88.50 |
| AVG Volume (30 Days) | ★ 5.5M | 493.8K |
| Earning Date | 11-18-2026 | 11-03-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 91.02 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $234,603,000.00 |
| Revenue This Year | N/A | $17.97 |
| Revenue Next Year | $22.56 | $36.88 |
| P/E Ratio | $20.64 | ★ N/A |
| Revenue Growth | N/A | ★ 157.01 |
| 52 Week Low | $2.45 | $29.49 |
| 52 Week High | $6.66 | $73.30 |
| Indicator | BORR | ANAB |
|---|---|---|
| Relative Strength Index (RSI) | 46.55 | 31.61 |
| Support Level | $4.10 | $43.75 |
| Resistance Level | $4.61 | $51.67 |
| Average True Range (ATR) | 0.19 | 2.24 |
| MACD | -0.03 | -0.45 |
| Stochastic Oscillator | 40.97 | 18.66 |
Borr Drilling Ltd is an offshore shallow-water drilling contractor providing services to the oil and gas industry. Its operations focus on the ownership, contracting, and operation of jack-up rigs in shallow-water areas, including the provision of related equipment and work crews to conduct oil and gas drilling and workover operations for exploration and production (E&P) customers. The company contracts its rigs on a dayrate basis to drill wells for integrated oil companies, state-owned national oil companies, and independent oil and gas companies. It operates in one reportable segment.
AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company is developing immune cell modulating antibodies, including two wholly owned checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases; rosnilimab, PD-1 agonist in a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA) and a Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis (UC); and ANB032, BTLA agonist, in a Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis (AD).